Non-volatile organic components of interest in the urine of humans using diapers are assayed by carrying out the following sequence of steps at least once and up to as many times as the diapers are changed in a given 24-hour period, namely: removing the outer cover and any extraneous mate rial from a used diaper so as to leave only diaper pulp with absorbed urine, estimating the amount of water in the used diaper, extracting a weighed portion of the diaper pulp with a water-miscible organic solvent, in which the diaper pulp is insoluble, to give an extract containing a component of interest, and determining the amount of the component of interest per unit volume of urine absorbed on the diaper pulp by analyzing an aliquot of the extract. The method may be applied e.g. to the prevention of sudden infant death syn drome in infants, by selecting infants for medication with melatonin where diaper urine indicates a deficiency of its metabolite 6-sulfatoxymelatonin in a 24-hour period. The melatonin may be administered in the form of a pharma ceutical formulation, or in an infant food which is included within the invention. In one aspect, this prior patent application (U.S. Ser. No. 07/697,714) relates to a pharmaceutical controlled-release formulation, which comprises melatonin in combination with at least one pharmaceutical carrier, diluent or coating, which formulation releases melatonin into the plasma fol lowing administration to a human patient, according to a profile which simulates that of the normal human endog enous melatonin profile depicted in FIG. 1 of that patent application.
In another aspect, the prior patent application (U.S. Ser. No. 07/697,714) relates to a method for correcting a mela tonin deficiency or distortion in the plasma melatonin level and profile in a human subject, which comprises adminis tering to a human in which such a deficiency or distortion had been diagnosed, over a time period including at least part of the nocturnal period, an effective plasma melatonin deficiency or distortion correcting amount of melatonin in the form of a pharmaceutical controlled-release formulation defined in the preceding paragraph.
In yet another aspect, the prior patent application (U.S. Ser. No. 071697,714) relates to a method for the prevention of sudden infant death syndrome in infants, which comprises the steps of: (a) screening at least one infant in order to determine the plasma melatonin level(s) thereof; (b) selecting at least one infant shown in step (a) to have a deficient plasma melatonin level; and (c) administering an effective plasma melatonin defi ciency correcting amount of melatonin to the at least one selected infant from step (b), the melatonin being in the form of a pharmaceutical controlled-release formulation defined above.
The entire contents of U.S. application Ser. No. 07/697, 714 are incorporated herein by reference.
U.S. Pat. No. 4,600,723 discloses the administration of melatonin in order to alleviate or prevent the negative effects of disturbances in circadian rhythms of bodily performance and function, such as may occur in a change of work patterns from day to night shift, or in cases of jet lag. Although conventional oral administration is exemplified, there is mentioned the possibility of administering melatonin a slow release form to maintain high plasma levels for the whole sleep period. It may be noted that sudden infant death syndrome (SIDS) or cot death is a phenomenon in which an apparently healthy infant of 1-12 months of age dies suddenly, usually duping sleep. It has been shown that while body and brain weight of age-matched control and SIDS infants were not signifi cantly different, the size of the pineal gland was significantly reduced in SIDS infants (p<0.000; Sparks and Hunsaker, J.
Pin. Res. 5:111 (1988) , and Abstract No. 127 of the 5th
Colloquium of the European Pineal Study Group, Guildford, U.K., Sep. 2, 1990) . Additionally, melatonin levels in the SIDS infant blood were lower by about 50% in SIDS compared with control infants (p<0.05; Wurtman and Lynch, Abstract No. 24 of the 5th Colloquium of the European Pineal Study Group, Guildford, U.K., Sep. 2, 1990) . If, as seems likely from these reports, melatonin serves a critical Pole in sleep functions of the human infant, administration of melatonin to infants with a deficient melatonin level (according to the method of U.S. application Ser. No. 07/697,714, or otherwise) could prevent SIDS.
It is evidently essential to be able to readily screen infants in the age group susceptible to SIDS, in order to determine their plasma melatonin levels, and to select infants for treatment with melatonin, in order to prevent SIDS, as far as possible.
More generally, determination of urine components is often desired for diagnostic purposes. These components may be, for example, hormones and metabolites such as corticosteroids, creatinine, uric acid and catecholamines.
Assays based on urine have several advantages over plasma assays, and in particular: (a) sample collection is non invasive, (b) frequent sample collection is readily achieved, (c) hormones and metabolites accumulate in urine and thus information is not lost if some time points in a sequence have been omitted, and (d) biosafety-whereas patients' specimens and kit calibration components should be handled as if capable of transmitting infections such as hepatitis B or AIDS, these risks are lower in urine samples compared with plasma samples.
For most purposes, urine samples are collected once, usually in the morning, or accumulated for 24 hours in a 5,500,225 3 reservoir, and samples of the total daily excretion are assessed. Plasma levels of most hormones, and consequently urinary levels of these hormones, and/or their metabolites, show regular diurnal fluctuations (circadian rhythms). To diagnose rhythm disturbances, these hormones need to be assessed in the blood or urine, at regular intervals over the 24 hour period, including during the night.
In infants (and in disabled or bedridden patients who do not control urine excretion), urine collection is complicated and is done by attachment to the urethral outlet of specially designed baskets. These devices are cumbersome and often become detached. Frequent sampling for assessment of circadian rhythm disturbances is almost impossible in such
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A very useful approach to facilitate chronobiological type diagnosis in infants (or in disabled or bedridden patients) would be to determine hormone or metabolite content in the diapers. However, such a method is limited by practical problems. A major drawback is associated with the fact that disposable diapers can absorb urine very efficiently (about 200 times their weight), but the urine cannot be recovered from the diapers, even by centrifugation. To extract mate rials from diapers, one needs to soak them with large volumes of water, which is not a suitable technique for mass diagnostic routines.
SUMMARY OF THE INVENTION
In accordance with the present invention, a method has been discovered for recovering urinary components from the diapers. This method facilitates urinary measurements in infants in general and in particular enables chronobiological diagnosis to be performed.
Thus, the present invention provides in one aspect a method for the determination of non-volatile organic com ponents of interest in the urine of human subjects using diapers, which comprises carrying out the following sequence of steps at least once and up to as many times as the-diapers are changed in a given 24-hour period, namely: providing a diaper which has been used to absorb urine from a human subject, removing the outer cover and any extra neous material so as to leave substantially only diaper pulp having urine absorbed thereon, estimating the amount of water in the used diaper, extracting a weighed portion of the diaper pulp having urine absorbed thereon with a water miscible organic solvent, in which the diaper pulp is insoluble, to give an extract containing a component of interest, and determining the amount of the component of interest per unit volume of urine which was absorbed on the diaper pulp by assaying an aliquot of the extract.
The water-miscible organic solvent may comprise e.g. at least one member selected from water-miscible alcohols, water-miscible acids, water-miscible bases, acetone, aceto nitrile, dimethylsulfoxide and water-miscible amides. The presently preferred solvent is selected from methanol and ethanol.
The component of interest may be e.g. selected from hormones and metabolites, e.g. corticosteroids, creatinine, uric acid or catecholamines. A particular component of interest is 6-sulfatoxymelatonin.
In another aspect, the invention provides a method for the prevention of sudden infant death syndrome in infants, which comprises the steps of: (a) screening one or more infants in order to determine the plasma melatonin level(s) thereof; (b) selecting infant(s) shown in step (a) to have a deficient plasma melatonin level as measured by a deficient The melatonin administered in step (c) may be, but is not necessarily, in the form of a pharmaceutical controlled release formulation. Such a slow-release formulation may be, but is not necessarily, such that melatonin is released therefrom in the body in simulation of the normal endog enous human melatonin plasma profile.
It will be appreciated that infants treated in accordance with the invention can be monitored in order to determine when it is safe to discontinue such administration which thus simulates the normal melatonin plasma profile. water-miscible alcohols: e.g. methanol, ethanol, propanol, isopropanol, tertiary butanol; water-miscible acids: e.g. formic acid, acetic acid, p-phe nolsulfonic acid; water-miscible bases: e.g. ethylamine, diethylamine, tri methylamine;
acetOne.
acetonitrile;
dimethylsulfoxide; water-miscible amides: e.g. dimethylformamide, pyrroli done, N-methylpyrrollidone. It will be appreciated that the above list is not exhaustive, and that the skilled person will be able to select one of these solvents or another water-miscible organic solvent e.g. according to the nature of the component(s) of interest or according to other relevant criteria known in the art.
As indicated above, the sequence of steps comprised in the method of the invention may be carried out only once, or any number of times on used diapers within a particular time period e.g. up to 24 hours, and, if desired (e.g. to assay metabolites released into the urine over a period) up to as many times as the diapers are changed in a given 24-hour period. In a particular embodiment, diapers used during a 10-24 hour period are retained and their time of replacement is noted.
The invention will be illustrated by the following non limiting Examples. As pointed out above, SIDS may be related to improper development of the pineal gland, which is a component of the circadian clock and produces melatonin. Abnormally low melatonin secretion can be positively identified by distorted rhythms in urinary excretion of the major melato nin metabolite, 6-sulfatoxymelatonin. Thus, we have assessed the development of circadian rhythms in 6-sulfa toxymelatonin excretion in a female infant as described below, (b) Extraction of urine components Diapers are collected during the course of one day, from a female infant at 4, 9 and 12 weeks after birth. The diapers are weighed, and the net water content of each one is calculated from the difference in weight between these used diapers and unused diapers of the same type and manufac ture. The external diaper layer is removed, including insoluble materials (faeces) to leave wet diaper pulp, from which a sample (0.1-0.5 g) is collected and weighed. The sample is extracted with methanol or ethanol for four hours at room temperature, and the mixture is kept overnight at 4 C. The insoluble pulpy fibers are then removed by centrifu gation (10,000 g/min), dried and weighed. Net pulpy water content is calculated by difference. c) Determination of 6-sulfatoxymelatonin in urine Aliquots of the extracts obtained in part (b), above, are diluted and assayed using standard procedures. In this case, urinary 6-sulfatoxymelatonin was measured by a sensitive radioimmunoassay method using 'I-labelled 2-iodo-6-sulfatoxymelatonin (Stockgrand, U.K.). (d) Assessment of extraction procedure efficiency A 6-sulfatoxymelatonin solution was poured onto an unused diaper and then extracted as described above. Recov ery of 6-sulfatoxymelatonin from the diaper was more than 95%(e) Assessment of extraction procedure reproducibility Samples were collected from various areas of the infant's wet diapers, and 6-sulfatoxymelatonin was extracted and assayed as described above.
The results of the assays described in parts (c) and (e), above, are shown respectively in Tables I and II below. It appears, therefore, that the results shown in Table I are those of an infant whose pineal gland is developing normally with respect to excretion of melatonin. In Example 1, above, there has been described inter alia the extraction of urine components, in particular 6-sulfa toxymelatonin, from diapers and quantitative determination of 6-sulfatoxymelatonin. However, as will be appreciated by skilled persons, the present invention is not limited to the determination of 6-sulfatoxymelatonin, but may also be applied to the determination of other urinary components. It will further be appreciated by skilled persons that even where the determination of 6-sulfatoxymelatonin is con cerned, this may be done by any appropriate method known in the art and is not restricted to a radioimmunoassay.
EXAMPLE 2
The general procedure described in parts (b) and (c) of
Example 1 was carried out on a 15 month-old male infant, with the detailed results shown in Table III . If a urinary assay such as has been described in Examples 1 and 2, above, reveals a deficiency in a component, e.g. a hormone, which should be present at a particular level in the subject's body, a physician of average competence would be able to prescribe medication in a particular dosage and form 5,500,225 7 of administration, to counteract such deficiency and to raise the component in question to the required level.
Thus, where by way of example determination of 6-sulfa toxymelatonin in the urine has revealed a melatonin defi ciency in the subject, a physician of average competence would be able to prescribe melatonin in a particular dosage and form of administration, to counteract such deficiency and to raise the level of melatonin to the required level. Where the subject is an infant, a physician or pediatrician would prescribe accordingly. Thus, the practitioner of aver age skill could select a suitable form of administration, e.g. from those described in the incorporated-by-reference docu ments mentioned above, or in particular could use a slow release formulation such as described in the present Example, from which melatonin is released in the body in simulation of the normal endogenous human melatonin plasma profile.
It is presently contemplated that a daily dosage rate for infants, whether to counteract a discovered deficiency or to prevent a deficiency occurring, i.e. for prophylactic use, could fall within the range of 1 g to 1 mg melatonin, either as a pharmaceutical formulation or include in a conventional solid or liquid infant food (including a food supplement). The present invention accordingly includes such an infant food, which, apart from the incorporation of melatonin in accordance with the present invention, would be manufac tured according to procedures known to persons in the art.
Preparation and Release Profile of Formulations
(a) There were compressed in a 7 mm cylindrical punch at 2.5 tons, after dry mixing of the powdered materials, namely 1 mg/tablet melatonin (Biosynth Co., Switzerland) and acrylic resin carrier (Rohm Pharma), which was Eudragit RS100 (formulation SR-Ms) or Eudragit RSPO (formulation SR-Mf), besides other components as noted:
formulation SR-Ms: Eudragit RS100 48.8%, lactose 50%, A conventional dosage form (RM) was prepared similarly to formulation SR-Mf, but using lactose in place of Eudragit as carrier.
(b) The potential release profile of the tablets prepared as described in paragraph (a), was first investigated by in vitro dissolution of melatonin therefrom in distilled water at 37 C. The results in Table A show the 96 of the melatonin content (mean value of 6 tablets) which has dissolved at the stated intervals of time. (c) The in vivo profile of the SR-Mf tablets prepared as described in paragraph (a), was investigated by oral admin istration twice to a healthy male (age 36) at 10 a.m., i.e. when circulating melatonin levels are undetectable. The amount of melatonin released in vivo was determined by radioimmunoassay of its major metabolite, 6-sulfatoxyme Table B show the melatonin determined as a % of the total melatonin administered (mean value of 2 tablets). (d) The data in Table B show that it is possible to make a pharmaceutical formulation which simulates the release of melatonin in the human body according to the normal human endogenous melatonin plasma profile. It is noted that the release of melatonin in vitro, illustrated in Table A, provides only an approximate indication of the in vivo release profile due to the known phenomenon of the active compound being absorbed by the tissues in the early stages of release.
While particular embodiments of the invention have been particularly described hereinabove, it will be appreciated that the present invention is not limited thereto, since, as will be readily apparent to skilled persons, many variations and modifications can be made. Such variations and modifica tions which have not been detailed herein are deemed to be the obvious equivalents of the present invention. For example, analogs of melatonin which substantially imitate the function of melatonin in the human body are deemed to be obvious chemical equivalents of melatonin. To take another instance, whereas the present method for assaying components of interest which is particularly described herein includes weighing used and unused diaper, and weighing a used diaper sample before and after extraction of such components, the skilled addressee will be aware that in the alternative, since creatinine (by way of example) is believed to be excreted in an approximately constant amount of 25 mg/kg of body weight per day, determination of the ratio of the component(s) of interest to creatinine could avoid the necessity for such weighings. This type of alter native, using such a ratio, is deemed to be an obvious equivalent of the method of the invention. The essential concept, spirit and scope of the present invention will be better understood in the light of the claims which follow.
We claim:
1. A method for the determination of non-volatile organic components of interest in the urine of human subjects using diapers, which comprises carrying out the following sequence of steps at least once and up to as many times as the diapers are changed in a given 24-hour period, namely:
providing a diaper which has been used to absorb urine from a human subject, removing the outer cover and any extra neous material so as to leave substantially only diaper pulp having urine absorbed thereon, estimating the amount of water in said used diaper, extracting a weighed portion of the diaper pulp having urine absorbed thereon with a water miscible organic solvent, in which the diaper pulp is insoluble, to give an extract containing a component of interest, and determining the amount of the component of interest per unit volume of urine which was absorbed on the diaper pulp by assaying an aliquot of said extract.
2. A method according to claim 1, wherein said water miscible organic solvent comprises at least one member selected from water-miscible alcohols, water-miscible acids, water-miscible bases, acetone, acetonitrile, dimethylsulfox ide and water-miscible amides. 6. A method according to claim 4, wherein said compo nent of interest is 6-sulfatoxymelatonin. 7. A method for the determination of 6-sulfatoxymelato nin in the urine of human subjects using diapers, which comprises carrying out the following sequence of steps at least once and up to as many times as the diapers are changed in a given 24-hour period, namely: providing a diaper which has been used to absorb urine from a human subject, removing the outer cover and any extraneous mate rialso as to leave substantially only diaper pulp having urine absorbed thereon, estimating the amount of water in said used diaper, extracting a weighed portion of the diaper pulp having urine absorbed thereon with a water-miscible organic solvent, in which the diaper pulp is insoluble, to give an extract containing 6-sulfatoxymelatonin, and determining the amount of 6-sulfatoxymelatonin per unit volume of urine which was absorbed on the diaper pulp by assaying an aliquot of said extract, and wherein said water-miscible organic solvent comprises at least one member selected from water-miscible alcohols, water-miscible acids, water-mis cible bases, acetone, acetonitrile, dimethylsulfoxide and water-miscible amides. 9. An infant food for use in preventing or counteracting a melatonin deficiency in infants, which includes an amount of melatonin based on an amount of such food suitable for ingestion in a 24-hour period, within the range of 1 pug to 1 mg melatonin.
10. A method for treating an infant susceptible to sudden infant death syndrome (SIDS) which comprises:
(a) screening infants to determine each infant's endog enous plasma melatonin level by measuring the amount of 6-sulfatoxymelatonin in the child's urine, (b) selecting at least one infant shown to have a deficient endogenous plasma melatonin level; and (c) administering to each of said infants melatonin in amounts sufficient to correct the plasma melatonin deficiency. 14. A method in accordance with claim 13, wherein said water-miscible alcohol comprises methanol or ethanol.
15. A method in accordance with claim 10, wherein the 6-sulfatoxymelatonin is measured over a 24 hour period. 18. A method of treating an infant susceptible to SIDS which comprises (a) screening infants to determine each infant's endog enous plasma melatonin level as measured by the profile of 6-sulfatoxymelatonin in the urine over a 24-hour period; (b) selecting at least one infant shown to have a deficient endogenous plasma melatonin profile; and (c) administering to each of said selected infants melato nin in amounts sufficient to correct the plasma mela tonin deficiency.
